Inozyme Pharma Inc (INZY) — Financial Flexibility Index
Inozyme Pharma Inc (INZY) has a Financial Flexibility Index of -0.46x as of March 2025. Free cash flow of $-29.15 Million (operating CF $-29.15 Million minus capex $0.00) represents 0% of total liabilities ($63.37 Million). Check INZY intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inozyme Pharma Inc Financial Flexibility Index (2018–2024)
Historical Financial Flexibility Index trend for Inozyme Pharma Inc across 7 annual periods. For the full cash flow conversion analysis, see cash efficiency ratio of Inozyme Pharma Inc.
Annual Financial Flexibility Index for Inozyme Pharma Inc (2018–2024)
Year-by-year free cash flow to debt coverage for Inozyme Pharma Inc. Explore INZY operating cash to total liabilities to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.41x | $-91.84 Million | $-91.91 Million | $65.36 Million | ▼ -20.5% |
| 2023 | -1.17x | $-70.38 Million | $-70.67 Million | $60.37 Million | ▲ +57.7% |
| 2022 | -2.76x | $-57.35 Million | $-57.76 Million | $20.80 Million | ▲ +17.6% |
| 2021 | -3.35x | $-47.76 Million | $-48.15 Million | $14.27 Million | ▼ -6.4% |
| 2020 | -3.14x | $-35.41 Million | $-35.97 Million | $11.26 Million | ▼ -1266.9% |
| 2019 | -0.23x | $-18.67 Million | $-18.81 Million | $81.16 Million | ▼ -43.9% |
| 2018 | -0.16x | $-9.18 Million | $-9.44 Million | $57.42 Million | — |